PET-MRI in Diagnosing Patients With Cancer, Cardiac Diseases, or Neurologic Diseases (NCT02084147) | Clinical Trial Compass
CompletedNot Applicable
PET-MRI in Diagnosing Patients With Cancer, Cardiac Diseases, or Neurologic Diseases
United States72 participantsStarted 2013-03-07
Plain-language summary
This randomized pilot clinical trial studies how well positron emission tomography (PET)-magnetic resonance imaging (MRI) works compared to standard-of-care PET-computed tomography (CT) in diagnosing patients with cancer, cardiac diseases, or neurologic diseases. PET-MRI combines two imaging methods that can be used to evaluate disease. PET-MRI is similar to standard-of-care PET-CT, but exposes the patient to less radiation. It is not yet known whether PET-MRI produces better image quality than PET-CT in diagnosing patients with cancer, cardiac disease, or neurologic disease.
Who can participate
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Clinically indicated PET/PET-CT (with or without clinically indicated diagnostic MRI)
* Presenting with one of the four conditions specified below
* Fludeoxyglucose F 18 (FDG) avid cancers
* Cardiac disease (cardiac viability assessment)
* Neurologic disorders (dementia)
* Inflammatory disease (for example fever of unknown origin, vasculitis, osteomyelitis)
Exclusion Criteria:
* Pregnancy and lactation
* Contraindications to undergo MRI
* Cardiac pacemaker and metal devices (as specified in a separate MRI Informed consent)
* Claustrophobia or inability to tolerate MRI examination (lay still for approximately 1 hour and hold breath intermittently)
* Previously known allergies against MRI contrast agents (exclusion criterion only for contrast enhanced MRI)
* Renal insufficiency: glomerular filtration rate (GFR) \< 40ml/min/1.73m\^2 and following European Society of Urogenital Radiology (ESUR) guidelines (exclusion criterion only for contrast enhanced MRI)
* Individuals who are not willing or capable of giving informed consent or assent (with legal guardian consent)
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Overall Image Quality Scores
Timeframe: Day 1
2
Lesion Based Standard Uptake Values (SUV)
Timeframe: Day 1
3
Area Under the Receiver Operating Characteristic Curve
Timeframe: Day 1
4
Time Effort Associated With the PET-MRI Versus PET-CT With MRI